nach oben

Clinical Drug Investigation

Erschienen in:

01.08.2013 | Original Research Article

Effects of Mitiglinide, a Short-Acting Insulin Secretagogue, on Daily Glycemic Variability and Oxidative Stress Markers in Japanese Patients with Type 2 Diabetes Mellitus

verfasst von: Noriko Kodani, Yoshifumi Saisho, Kumiko Tanaka, Toshihide Kawai, Hiroshi Itoh

Erschienen in: Clinical Drug Investigation | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and Objective

The objective of this study was to clarify the effects of mitiglinide on daily glycemic variability and oxidative stress markers in outpatients with type 2 diabetes mellitus that is insufficiently controlled by diet and/or non-insulin secretagogues.

Methods

We enrolled 24 patients with type 2 diabetes whose glycemic control had been suboptimal [i.e. glycosylated hemoglobin (HbA_1c) ≥6.9 %]. The patients were treated with mitiglinide 10 mg three times daily for 16 weeks. If their glycemic control was not improved at week 8, the dose of mitiglinide was increased to 20 mg three times daily. Daily glycemic variability was assessed by 7-point self-monitoring of blood glucose for 2 days, and standard deviation (SD), M value, and mean of daily differences (MODD) were calculated. Oxidative stress was assessed by oxidized low-density lipoprotein, pentosidine, urinary 8-iso-prostaglandin F2alpha, and urinary 8-hydroxydeoxy guanosine.

Results

After 16 weeks of mitiglinide treatment, the HbA_1c level was significantly decreased (mean ± SD, 7.4 ± 0.7 to 6.8 ± 0.5 %, P < 0.0001). Postprandial glucose excursion and glycemic variability were also significantly improved after mitiglinide treatment (all P < 0.05). The reductions in SD, M value, and MODD were 17, 50, and 48 %, respectively. There was a significant positive correlation between the change in HbA_1c and change in SD during the study (r = 0.454, P = 0.03). There were no significant changes in oxidative stress markers.

Conclusions

The present study supports the notion that mitiglinide improves postprandial glucose excursion and HbA_1c level in patients with type 2 diabetes. In addition, we demonstrated that mitiglinide also effectively improves daily glycemic variability. The effect of mitiglinide on oxidative stress needs further investigation.

Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev. 2002;18(Suppl 3):S9–13.PubMedCrossRef

Saito I. Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan. Circ J. 2012;76:1066–73.PubMedCrossRef

DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397–405.CrossRef

DECODA Study Group, International Diabetes Epidemiology Group. Cardiovascular risk profile assessment in glucose-intolerant Asian individuals—an evaluation of the World Health Organization two-step strategy: the DECODA study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia). Diabet Med. 2002;19:549–57.CrossRef

Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91:813–9.PubMedCrossRef

Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.PubMedCrossRef

Nakagami T, The DECODA Study Group. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47:385–94.PubMedCrossRef

Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–70.PubMedCrossRef

Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067–72.PubMedCrossRef

10.

Ceriello A. New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care. 2003;26:1589–96.PubMedCrossRef

11.

Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681–7.PubMedCrossRef

12.

Kaiser N, Nesher R, Oprescu A, et al. Characterization of the action of S 21403 (mitiglinide) on insulin secretion and biosynthesis in normal and diabetic beta-cells. Br J Pharmacol. 2005;146:872–81.PubMedCrossRef

13.

Konya H, Miuchi M, Konishi K, et al. Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. J Int Med Res. 2009;37:1904–12.PubMedCrossRef

14.

Pratley RE, Foley JE, Dunning BE. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des. 2001;7:1375–97.PubMedCrossRef

15.

Ohnota H, Koizumi T, Tsutsumi N, et al. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther. 1994;269:489–95.PubMed

16.

Assaloni R, Da Ros R, Quagliaro L, et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia. 2005;48:1919–24.PubMedCrossRef

17.

Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig. 2012;2012(3):39–40.CrossRef

18.

Yoshiuchi K, Matsuhisa M, Katakami N, et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J. 2008;55:503–7.PubMedCrossRef

19.

Saisho Y, Tanaka K, Abe T, et al. Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. Diabetol Int. 2011;2:146–53.CrossRef

20.

Nakano M, Kawanishi Y, Kamohara S, et al. Oxidative DNA damage (8-hydroxydeoxyguanosine) and body iron status: a study on 2507 healthy people. Free Radic Biol Med. 2003;35:826–32.PubMedCrossRef

21.

Schlichtkrull J, Munck O, Jersild M. The M-valve, an index of blood sugar control in diabetics. Acta Med Scand. 1965;177:95–102.PubMedCrossRef

22.

Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia. 1972;8:342–8.PubMedCrossRef

23.

Saisho Y, Shimada A, Kawai T, et al. Effectiveness of switching from mitiglinide 30 mg or nateglinide 270 mg daily to mitiglinide 60 mg daily on glycemic control and body weight in type 2 diabetic patients. J New Rem Clin. 2010;59:950–9.

24.

Gao X. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res. 2009;37:812–21.PubMedCrossRef

25.

Kaku K, Tanaka S, Origasa H, et al. Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. Endocr J. 2009;56:739–46.PubMedCrossRef

26.

Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract. 2006;12(Suppl 1):25–30.PubMedCrossRef

27.

Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.PubMedCrossRef

28.

Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab. 2008;93:1345–50.PubMedCrossRef

29.

Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57:1349–54.PubMedCrossRef

30.

Kondo A, Manabe M, Saito K, et al. Insulin treatment prevents LDL from accelerated oxidation in patients with diabetes. J Atheroscler Thromb. 2002;9:280–7.PubMedCrossRef

31.

Su Y, Xu Y, Sun YM, et al. Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol. 2010;55:21–5.PubMedCrossRef

32.

Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRef

33.

Monnier L, Colette C, Mas E, et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia. 2010;53:562–71.PubMedCrossRef

34.

Seaquist ER, Kahn SE, Clark PM, et al. Hyperproinsulinemia is associated with increased beta cell demand after hemipancreatectomy in humans. J Clin Investig. 1996;97:455–60.PubMedCrossRef

35.

Inoguchi T, Umeda F, Kakimoto M, et al. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Endocr J. 2000;47:763–70.PubMedCrossRef

Titel: Effects of Mitiglinide, a Short-Acting Insulin Secretagogue, on Daily Glycemic Variability and Oxidative Stress Markers in Japanese Patients with Type 2 Diabetes Mellitus
verfasst von: Noriko Kodani
Yoshifumi Saisho
Kumiko Tanaka
Toshihide Kawai
Hiroshi Itoh
Publikationsdatum: 01.08.2013
Verlag: Springer International Publishing
Erschienen in: Clinical Drug Investigation / Ausgabe 8/2013
Print ISSN: 1173-2563
Elektronische ISSN: 1179-1918
DOI: https://doi.org/10.1007/s40261-013-0098-5

Springer Medizin

Abstract

Background and Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2013

Effectiveness and Tolerability of a Trandolapril-Based Antihypertensive Treatment Regimen over 12 months in Actual Clinical Care Across Canada

Effect of Sugammadex on QT/QTc Interval Prolongation when Combined with QTc-Prolonging Sevoflurane or Propofol Anaesthesia

Psychotropic Prescription Patterns Among Patients Diagnosed With Depressive Disorder Based on Claims Database in Japan

Population Pharmacokinetics of Dexmedetomidine in Critically Ill Patients

A National Survey Examining Obstetrician Perspectives on Use of 17-Alpha Hydroxyprogesterone Caproate Post-US FDA Approval

A Clinical Study to Examine the Potential Effect of Lansoprazole on the Pharmacokinetics of Bosutinib when Administered Concomitantly to Healthy Subjects